Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure.
作者信息
Damiani Marianna, Gandini Lucia, Landi Francesco, Borleri Gianmaria, Fabretti Fabrizio, Gritti Giuseppe, Riva Ivano
机构信息
Postgraduate School of Anesthesiology and Intensive Care, University of Milan, Milan, Italy; Intensive Care Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Hematology Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
出版信息
Respir Med. 2021 Aug-Sep;185:106477. doi: 10.1016/j.rmed.2021.106477. Epub 2021 May 26.
Abstract
摘要
相似文献
1
Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure.
Respir Med. 2021 Aug-Sep;185:106477. doi: 10.1016/j.rmed.2021.106477. Epub 2021 May 26.
2
Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia.
Blood Purif. 2021;50(4-5):566-571. doi: 10.1159/000511725. Epub 2020 Nov 12.
3
Hemadsorption as a Treatment Option for Multisystem Inflammatory Syndrome in Children Associated With COVID-19. A Case Report.
Front Immunol. 2021 Jun 1;12:665824. doi: 10.3389/fimmu.2021.665824. eCollection 2021.
4
Successful Recovery from COVID-19-associated Acute Respiratory Failure with Polymyxin B-immobilized Fiber Column-direct Hemoperfusion.
Intern Med. 2020 Oct 1;59(19):2405-2408. doi: 10.2169/internalmedicine.5413-20. Epub 2020 Aug 29.
5
COVID-19: Hyperinflammatory Syndrome and Hemoadsorption with CytoSorb.
Blood Purif. 2021;50(6):976-978. doi: 10.1159/000512199. Epub 2020 Dec 16.
6
Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.
Blood Purif. 2021;50(2):257-260. doi: 10.1159/000509107. Epub 2020 Jun 26.
7
Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report.
Blood Purif. 2021;50(4-5):575-577. doi: 10.1159/000512982. Epub 2020 Dec 2.
8
Successful mobile extracorporeal membrane oxygenator for COVID-19 severe respiratory failure.
J Card Surg. 2020 Dec;35(12):3655-3657. doi: 10.1111/jocs.15106. Epub 2020 Oct 10.
9
Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.
Int J Infect Dis. 2020 Jul;96:618-620. doi: 10.1016/j.ijid.2020.05.065. Epub 2020 May 26.
10
Literature Review of Hemadsorption Therapy in Severe COVID-19 Cases: a Narrative Review.
Clin Lab. 2022 Feb 1;68(2). doi: 10.7754/Clin.Lab.2021.210839.
引用本文的文献
1
The COSMOS Registry of CytoSorb Hemoadsorption Therapy in Critically Ill Patients: Protocol for an International, Prospective Registry.
JMIR Res Protoc. 2024 Nov 5;13:e55880. doi: 10.2196/55880.
2
Impact of extracorporeal hemadsorption on mortality in critically ill COVID-19 patients in the intensive care unit.
Int J Artif Organs. 2024 Oct;47(10):736-742. doi: 10.1177/03913988241269527. Epub 2024 Sep 13.
3
Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption.
J Anesth Analg Crit Care. 2022 Apr 4;2(1):15. doi: 10.1186/s44158-022-00043-w.
4
CytoSorb in patients with coronavirus disease 2019: A rapid evidence review and meta-analysis.
Front Immunol. 2023 Jan 31;14:1067214. doi: 10.3389/fimmu.2023.1067214. eCollection 2023.
5
Sepsis Management in Southeast Asia: A Review and Clinical Experience.
J Clin Med. 2022 Jun 23;11(13):3635. doi: 10.3390/jcm11133635.
6
Cytokine Hemoadsorption as Rescue Therapy for Critically Ill Patients With SARS-CoV-2 Pneumonia With Severe Respiratory Failure and Hypercytokinemia.
Front Med (Lausanne). 2022 Jan 10;8:779038. doi: 10.3389/fmed.2021.779038. eCollection 2021.
7
Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study.
Blood Purif. 2022;51(3):233-242. doi: 10.1159/000515627. Epub 2021 Jun 14.
8
Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series.
Braz J Cardiovasc Surg. 2022 Mar 10;37(1):35-47. doi: 10.21470/1678-9741-2020-0403.
9
Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines.
Open Biol. 2020 Sep;10(9):200160. doi: 10.1098/rsob.200160. Epub 2020 Sep 23.
本文引用的文献
1
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.
Leukemia. 2021 Sep;35(9):2710-2714. doi: 10.1038/s41375-021-01299-x. Epub 2021 May 24.
2
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19.
Nat Immunol. 2021 Jan;22(1):19-24. doi: 10.1038/s41590-020-00832-x. Epub 2020 Nov 18.
3
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Immunobiology. 2020 Nov;225(6):152001. doi: 10.1016/j.imbio.2020.152001. Epub 2020 Aug 9.
4
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
5
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
6
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.
Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2.
Zotero 插件